Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: A study with risperidone long-acting injection

International Clinical Psychopharmacology

Volumn 23, Issue 6, 2008, Pages 325-331

  Emsley, Robin ^a   Oosthuizen, Petrus ^a   Koen, Liezl ^a   Niehaus, Dana J H ^a   Medori, Rossella ^b   Rabinowitz, Jonathan ^c  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b Janssen Cilag EMEA Belgium   (Belgium)

^c BAR ILAN UNIVERSITY   (Israel)

Author keywords

Long acting injectable; Remission; Risperidone; Schizophrenia

Indexed keywords

BIPERIDEN; FLUOXETINE; LORAZEPAM; ORPHENADRINE; PROPRANOLOL; RISPERIDONE;

ADOLESCENT; ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS; MALE; PROSPECTIVE STUDIES; REMISSION INDUCTION; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 55849131073     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32830c2042     Document Type: Article

References (42)

1. Addington D, Addington J, Maticka-Tyndale E, Joyce J (1992). Reliability and validity of a Depression Rating Scale for schizophrenics. Schizophr Res 6:201-208.
2. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders. Washington DC: American Psychiatric Association.
3. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR (2005). Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162:441-449.
4. Arango C, Kirkpatrick B, Buchanan RW (2000). Neurological signs and the heterogeneity of schizophrenia. Am J Psychiatry 157:560-565.
5. Buckley PF, Harvey PD, Bowie CR, Loebel A (2007a). The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. Schizophr Res 94:99-106.
6. Buckley PF, Wirshing DA, Bhushan P, Pierre JM, Resnick SA, Wirshing WC (2007b). Lack of insight in schizophrenia: impact on treatment adherence. CNS Drugs 21:129-141.
7. Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Woerner M, et al. (1995). Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 152:1724-1729.
8. Chouinard G, Margolese H (2005). Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 76:247-265.
9. Coldham EL, Addington J, Addington D (2002). Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 106: 286-290.
10. Correll CU, Malhotra AK, Kaushik S, Mcmeniman M, Kane JM (2003). Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 160:2063-2065.
11. Csernansky JG, Mahmoud R, Brenner R (2002). A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346:16-22.
12. De Hert M, Van Winkel R, Wampers M, Kane J, Van Os J, Peuskens J (2007). Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophr Res 92:68-73.
13. Drake RJ, Dunn G, Tarrier N, Bentall RP, Haddock G, Lewis SW (2007). Insight as a predictor of the outcome of first-episode nonaffective psychosis in a prospective cohort study in England. J Clin Psychiatry 68:81-86.
14. Emsley R, Oosthuizen PP, Kidd M, Koen L, Niehaus D J, Turner HJ (2006). Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J Clin Psychiatry 67: 1707-1712.
15. Emsley R, Rabinowitz J, Medori R (2007). Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res 89:129-139.
16. Emsley R, Oosthuizen P, Koen L, Niehaus D, Medori R, Rabinowitz J (2008). Long-acting injectable risperidone in the treatment of subjects with recent onset psychosis: a preliminary study. J Clin Psychopharmacol 28:210-213.
17. Gharabawi G, Bossie C, Turkoz I, Kujawa M, Mahmoud R, Simpson G (2007). The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. J Nerv Ment Dis 195:976-982.
18. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health, US Department of Health Education and Welfare.
19. Helldin L, Kane JM, Karilampi U, Norlander T, Archer T (2006). Remission and cognitive ability in a cohort of patients with schizophrenia. J Psychiatr Res 40:738-745.
20. Helldin L, Kane JM, Karilampi U, Norlander T, Archer T (2007). Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders. Schizophr Res 93:160-168.
21. Hogan TP, Awad AG (2000). Drug Attitude Inventory. Handbook of Psychiatric Measures. Washington DC: American Psychiatric Association.
22. International Conference on Harmonization (1999). ICH Harmonized Tripartite Guidelines for Good Clinical Practice. Stat Med 18:1905-1942.
23. Kane JM (2006). Utilization of long-acting antipsychotic medication in patient care. CNS Spectr 11:1-7; quiz 7-8.
24. Kane JM, Crandall DT, Marcus RN, Eudicone J, Pikalov A 3rd, Carson WH, Swyzen W (2007). Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr Res 95:143-150.
25. Kay SR, Fiszbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
26. Keshavan MS, Rabinowitz J, Desmedt G, Harvey PD, Schooler N (2004). Correlates of insight in first episode psychosis. Schizophr Res 70:187-194.
27. Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, et al. (1993). Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 50:369-376.
28. Lincoln TM, Lullmann E, Rief W (2007). Correlates and Long-Term Consequences of Poor Insight in Patients With Schizophrenia. A Systematic Review. Schizophr Bull 33:1324-1342.
29. Marder SR, Davis JM, Chouinard G (1997). The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58:538-546.
30. Murray RM, Van Os J (1998). Predictors of outcome in schizophrenia. J Clin Psychopharmacol 18:2S-4S.
31. Nasrallah HA, Lasser R (2006). Improving patient outcomes in schizophrenia: achieving remission. J Psychopharmacol 20:57-61.
32. Oosthuizen P, Emsley R, Niehaus D, Koen L, Chiliza B (2006). The relationships between depression and remission in first-episode psychosis. World Psychiatry 5:172-176.
33. Rabinowitz J, Levine SZ, Medori R, Oosthuizen P, Koen L, Emsley R (2007). Concordance of patient and clinical ratings of symptom severity and change of psychotic illness. Schizophr Res 100: 359-360.
34. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. (1999a). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56:241-247.
35. Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, et al. (1999b). Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 156:544-549.
36. Saeedi H, Addington J, Addington D (2007). The association of insight with psychotic symptoms, depression, and cognition in early psychosis: a 3-year follow-up. Schizophr Res 89:123-128.
37. Sanz M, Constable G, Lopez-ibor I, Kemp R, David AS (1998). A comparative study of insight scales and their relationship to psychopathological and clinical variables. Psychol Med 28:437-446.
38. Shad MU, Keshavan MS, Tamminga CA, Cullum CM, David A (2007). Neurobiological underpinnings of insight deficits in schizophrenia. Int Rev Psychiatry 19:437-446.
39. Ucok A, Polat A, Genc A, Cakiotar S, Turan N (2004). Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia. J Psychiatr Res 38:163-168.
40. Van Os J, Drukker M, Acampo J, Meijer J, Bak M, Delespaul P (2006). Validation of remission criteria for schizophrenia. Am J Psychiatry 163:2000-2002.
41. Ware J Jr, Kosinski M, Keller SD (1996). A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 34:220-233.
42. Wunderink L, Nienhuis FJ, Sytema S, Wiersma D (2007). Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics. Schizophr Bull 33:792-796.